SG11201908870PA - Methods of preventing or treating ophthalmic diseases - Google Patents
Methods of preventing or treating ophthalmic diseasesInfo
- Publication number
- SG11201908870PA SG11201908870PA SG11201908870PA SG11201908870PA SG 11201908870P A SG11201908870P A SG 11201908870PA SG 11201908870P A SG11201908870P A SG 11201908870PA SG 11201908870P A SG11201908870P A SG 11201908870PA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- basel
- pct
- preventing
- ophthalmic diseases
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 4
- 102220240796 rs553605556 Human genes 0.000 abstract 2
- 229940126033 PPAR agonist Drugs 0.000 abstract 1
- 239000000969 carrier Substances 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 abstract 1
- 239000002307 peroxisome proliferator activated receptor agonist Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date ill Hu omits I El ° RIM 100 HOM IMO 011 (10) International Publication Number WO 2018/185098 Al 11 October 2018 (11.10.2018) WIPO I PCT (51) International Patent Classification: TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, A61K 31/167 (2006.01) A61K 31/4439 (2006.01) KM, ML, MR, NE, SN, TD, TG). A61K 31/195 (2006.01) A61K 31/4965 (2006.01) A61K 31/216 (2006.01) A61K 31/496 (2006.01) Declarations under Rule 4.17: A61K 31/415 (2006.01) A61K 31/506 (2006.01) as to applicant's entitlement to apply for and be granted a A61K 31/416 (2006.01) A61K 31/519 (2006.01) patent (Rule 4.17(ii)) A61K 31/427 (2006.01) A61K 31/53 (2006.01) A61K 31/437 (2006.01) A61K 45/06 (2006.01) Published: A61K 31/438 (2006.01) A61K 9/00 (2006.01) — with international search report (Art. 21(3)) A61K 31/155 (2006.01) A61P 27/00 (2006.01) A61K 31/4412 (2006.01) A61P 27/06 (2006.01) A61K 31/4418 (2006.01) (21) International Application Number: PCT/EP2018/058486 (22) International Filing Date: 03 April 2018 (03.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 17164765.4 04 April 2017 (04.04.2017) EP (71) Applicant: STREKIN AG [CH/CH]; Hochbergerstr. 60C, 4057 Basel (CH). (72) Inventors: BAUSCH, Alexander; Stettenweg 16, 4125 Riehen (CH). WRIGHT, Matthew; c/o Strekin AG Hochbergerstr. 60C, 4057 Basel (CH). (74) Agent: SCHOLLHORN, Andreas; Latscha Schollhorn Partner AG Austrasse 24, 4051 Basel (CH). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (54) Title: METHODS OF PREVENTING OR TREATING OPHTHALMIC DISEASES 1-1 0 (57) : The present invention relates to a pharmaceutical combination comprising: (a) a PPAR agonist; (b) a p38 kinase inhibitor; \" and optionally (c) one or more pharmaceutically acceptable diluents, excipients or carriers for use in a method of preventing or treating 0 ophthalmic diseases or disorders in a subject.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17164765 | 2017-04-04 | ||
PCT/EP2018/058486 WO2018185098A1 (en) | 2017-04-04 | 2018-04-03 | Methods of preventing or treating ophthalmic diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201908870PA true SG11201908870PA (en) | 2019-10-30 |
Family
ID=58489554
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202110804WA SG10202110804WA (en) | 2017-04-04 | 2018-04-03 | Methods of preventing or treating ophthalmic diseases |
SG11201908870P SG11201908870PA (en) | 2017-04-04 | 2018-04-03 | Methods of preventing or treating ophthalmic diseases |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202110804WA SG10202110804WA (en) | 2017-04-04 | 2018-04-03 | Methods of preventing or treating ophthalmic diseases |
Country Status (19)
Country | Link |
---|---|
US (1) | US11576916B2 (en) |
EP (1) | EP3606514A1 (en) |
JP (1) | JP7356352B2 (en) |
KR (1) | KR20190137854A (en) |
CN (1) | CN110636840A (en) |
AU (2) | AU2018248578A1 (en) |
BR (1) | BR112019020754A2 (en) |
CA (1) | CA3058820A1 (en) |
CL (1) | CL2019002808A1 (en) |
EA (1) | EA201992004A1 (en) |
IL (1) | IL269698B (en) |
MA (1) | MA49040A (en) |
MY (1) | MY202289A (en) |
NZ (1) | NZ757557A (en) |
PH (1) | PH12019550199A1 (en) |
SG (2) | SG10202110804WA (en) |
UA (1) | UA127245C2 (en) |
WO (1) | WO2018185098A1 (en) |
ZA (1) | ZA201907101B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201821138D0 (en) * | 2018-12-21 | 2019-02-06 | Benevolentai Bio Ltd | Compositions and uses thereof |
US20230172919A1 (en) * | 2020-03-26 | 2023-06-08 | Sorbonne Universite | An insulin sensitizer for use in the prevention and/or treatment of the damages caused by retinal detachment |
US20230263803A1 (en) * | 2020-08-11 | 2023-08-24 | Kinarus Ag | Methods of preventing or treating covid-19 and related viral diseases or disorders |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR240698A1 (en) | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Process for the preparation of 5-(4-(2-(5-ethyl-2-pyridil)-ethoxy)benzyl)-2,4-thiazolodinedione and their salts |
CA2434834C (en) * | 2001-02-12 | 2010-09-14 | F. Hoffmann-La Roche Ag | 6-substituted pyrido-pyrimidines |
RU2324695C2 (en) | 2002-08-06 | 2008-05-20 | Ф.Хоффманн-Ля Рош Аг | 6-ALCOXYPYRIDOPYRIMIDINES AND PHARMACEUTICAL COMPOUND POSSESSING ACTIVITY OF MAP p38 KINASE INHIBITORS |
EP1685131B1 (en) * | 2003-11-13 | 2007-03-07 | F. Hoffmann-La Roche AG | Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones |
US7662389B2 (en) | 2003-12-17 | 2010-02-16 | Alcon, Inc. | Use of serum amyloid A gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents |
WO2008057933A2 (en) * | 2006-11-02 | 2008-05-15 | Aestus Therapeutics, Inc. | Methods of treating neuropathic pain by modulation of glycogenolysis or glycolysis pathways |
CN101679211A (en) | 2007-06-15 | 2010-03-24 | 霍夫曼-拉罗奇有限公司 | Be used to prepare 3-amino-penta-1, the novel method of 5-glycol |
WO2010048446A2 (en) * | 2008-10-22 | 2010-04-29 | Genentech, Inc. | Modulation of axon degeneration |
JP2010235535A (en) * | 2009-03-31 | 2010-10-21 | Santen Pharmaceut Co Ltd | Preventive or therapeutic agent of chorioretinopathy containing ppar alpha agonist as active ingredient |
EP3089748A4 (en) * | 2014-01-02 | 2017-09-27 | Massachusetts Eye & Ear Infirmary | Treating ocular neovascularization |
-
2018
- 2018-04-03 AU AU2018248578A patent/AU2018248578A1/en not_active Abandoned
- 2018-04-03 MA MA049040A patent/MA49040A/en unknown
- 2018-04-03 EA EA201992004A patent/EA201992004A1/en unknown
- 2018-04-03 SG SG10202110804WA patent/SG10202110804WA/en unknown
- 2018-04-03 BR BR112019020754A patent/BR112019020754A2/en unknown
- 2018-04-03 JP JP2019554865A patent/JP7356352B2/en active Active
- 2018-04-03 SG SG11201908870P patent/SG11201908870PA/en unknown
- 2018-04-03 US US16/500,504 patent/US11576916B2/en active Active
- 2018-04-03 MY MYPI2019005621A patent/MY202289A/en unknown
- 2018-04-03 CN CN201880023640.0A patent/CN110636840A/en active Pending
- 2018-04-03 EP EP18716575.8A patent/EP3606514A1/en active Pending
- 2018-04-03 WO PCT/EP2018/058486 patent/WO2018185098A1/en active Application Filing
- 2018-04-03 UA UAA201910137A patent/UA127245C2/en unknown
- 2018-04-03 CA CA3058820A patent/CA3058820A1/en active Pending
- 2018-04-03 KR KR1020197032636A patent/KR20190137854A/en not_active Application Discontinuation
- 2018-04-03 NZ NZ757557A patent/NZ757557A/en unknown
-
2019
- 2019-09-25 PH PH12019550199A patent/PH12019550199A1/en unknown
- 2019-09-26 IL IL269698A patent/IL269698B/en unknown
- 2019-10-02 CL CL2019002808A patent/CL2019002808A1/en unknown
- 2019-10-28 ZA ZA2019/07101A patent/ZA201907101B/en unknown
-
2024
- 2024-04-11 AU AU2024202380A patent/AU2024202380A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
PH12019550199A1 (en) | 2020-09-14 |
AU2024202380A1 (en) | 2024-05-02 |
JP7356352B2 (en) | 2023-10-04 |
CA3058820A1 (en) | 2018-10-11 |
CN110636840A (en) | 2019-12-31 |
EA201992004A1 (en) | 2020-02-20 |
IL269698B (en) | 2022-04-01 |
US20200061069A1 (en) | 2020-02-27 |
UA127245C2 (en) | 2023-06-21 |
NZ757557A (en) | 2022-10-28 |
CL2019002808A1 (en) | 2020-05-22 |
KR20190137854A (en) | 2019-12-11 |
MY202289A (en) | 2024-04-22 |
WO2018185098A1 (en) | 2018-10-11 |
EP3606514A1 (en) | 2020-02-12 |
MA49040A (en) | 2020-02-12 |
SG10202110804WA (en) | 2021-11-29 |
IL269698A (en) | 2019-11-28 |
JP2020513017A (en) | 2020-04-30 |
ZA201907101B (en) | 2024-01-31 |
US11576916B2 (en) | 2023-02-14 |
AU2018248578A1 (en) | 2019-10-17 |
BR112019020754A2 (en) | 2020-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201811491YA (en) | Quinazoline and indole compounds to treat medical disorders | |
SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
SG11201900163PA (en) | Macrocycle kinase inhibitors | |
SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
SG11201805001UA (en) | Method of treating influenza a |